S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
BREAKING: Tiny biotech successfully treats blindness (Ad)
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
BREAKING: Tiny biotech successfully treats blindness (Ad)
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
BREAKING: Tiny biotech successfully treats blindness (Ad)
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
BREAKING: Tiny biotech successfully treats blindness (Ad)
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
NASDAQ:ARDX

Ardelyx - ARDX Stock Forecast, Price & News

$4.06
+0.14 (+3.57%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.94
$4.23
50-Day Range
$2.75
$4.14
52-Week Range
$0.49
$4.23
Volume
6.64 million shs
Average Volume
7.65 million shs
Market Capitalization
$838.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Ardelyx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
47.8% Upside
$6.00 Price Target
Short Interest
Bearish
5.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.32
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$60,225 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.30) to $0.25 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

300th out of 989 stocks

Pharmaceutical Preparations Industry

126th out of 480 stocks


ARDX stock logo

About Ardelyx (NASDAQ:ARDX) Stock

Ardelyx, Inc. is a biopharmaceutical company. It engages in the research, development, and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Waltham, MA.

Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

ARDX Stock News Headlines

Ardelyx (NASDAQ:ARDX) Shares Down 6.7%
Ardelyx (NASDAQ:ARDX) Upgraded by StockNews.com to Buy
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Are Medical Stocks Lagging Ardelyx (ARDX) This Year?
Ardelyx (ARDX) Gains As Market Dips: What You Should Know
FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)
Why Is Ardelyx (ARDX) Stock Up 38% Today?
See More Headlines
Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

ARDX Company Calendar

Last Earnings
11/12/2021
Today
3/24/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARDX
Employees
86
Year Founded
2007

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+47.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-67,210,000.00
Net Margins
-128.85%
Pretax Margin
-128.84%

Debt

Sales & Book Value

Annual Sales
$52.16 million
Book Value
$0.50 per share

Miscellaneous

Free Float
194,103,000
Market Cap
$838.36 million
Optionable
Optionable
Beta
1.10

Social Links


Key Executives

  • Mike Raab
    President, Chief Executive Officer & Director
  • Justin A. Renz
    Chief Financial, Operations Officer & Treasurer
  • Laura A. Williams
    Chief Medical Officer
  • Elizabeth GrammerElizabeth Grammer
    Secretary, Chief Legal & Administrative Officer
  • David P. Rosenbaum
    Chief Development Officer













ARDX Stock - Frequently Asked Questions

Should I buy or sell Ardelyx stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings
or view top-rated stocks.

What is Ardelyx's stock price forecast for 2023?

4 brokers have issued 12-month price targets for Ardelyx's stock. Their ARDX share price forecasts range from $3.00 to $8.00. On average, they predict the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 47.8% from the stock's current price.
View analysts price targets for ARDX
or view top-rated stocks among Wall Street analysts.

How have ARDX shares performed in 2023?

Ardelyx's stock was trading at $2.85 at the beginning of 2023. Since then, ARDX shares have increased by 42.5% and is now trading at $4.06.
View the best growth stocks for 2023 here
.

Are investors shorting Ardelyx?

Ardelyx saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 10,990,000 shares, an increase of 8.7% from the February 13th total of 10,110,000 shares. Based on an average trading volume of 7,590,000 shares, the short-interest ratio is currently 1.4 days.
View Ardelyx's Short Interest
.

When is Ardelyx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ARDX earnings forecast
.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) released its quarterly earnings data on Friday, November, 12th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.07. The biopharmaceutical company had revenue of $1.17 million for the quarter, compared to analyst estimates of $0.85 million. Ardelyx had a negative trailing twelve-month return on equity of 95.19% and a negative net margin of 128.85%.

What ETFs hold Ardelyx's stock?

ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB).

What other stocks do shareholders of Ardelyx own?
What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Orchard Capital Management LLC (1.46%), Two Sigma Investments LP (1.18%), Price T Rowe Associates Inc. MD (1.16%), Lion Point Capital LP (0.95%), Geode Capital Management LLC (0.87%) and Pekin Hardy Strauss Inc. (0.84%). Insiders that own company stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends
.

How do I buy shares of Ardelyx?

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $4.06.

How much money does Ardelyx make?

Ardelyx (NASDAQ:ARDX) has a market capitalization of $838.36 million and generates $52.16 million in revenue each year. The biopharmaceutical company earns $-67,210,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The official website for the company is www.ardelyx.com. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at investor@ardelyx.com, or via fax at 510-745-0493.

This page (NASDAQ:ARDX) was last updated on 3/24/2023 by MarketBeat.com Staff